THE INCIDENCE OF DYSLIPIDEMIA AND DIABETES MELLITUS TYPE 2 AMONG PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS USING THE FIRST LINE HIGHLY ACTIVE ANTIRETRO-VIRAL THERAPY FOR AT LEAST TWELVE MONTHS IN SOUTHERN PHILIPPINES HIV-AIDS CORE TEAM HUB

Abstract

INTRODUCTION
The introduction of highly active antiretroviral therapy has improved the survival rate of people living with HIV. However co-morbid conditions such as cardiovascular disease have emerged. Risk factors identified include dyslipidemia and toxicity from ART. Some of the metabolic complications of chronic use of HAART include Diabetes mellitus type 2 (DM type 2) and dyslipidemia.

METHODOLOGY
This study is a retrospective analytical study. All patients with HIV enrolled in SPMC HACT treatment hub who are on first line HAART and who have given their verbal consent were included. Data were gathered through a chart review from the medical records.

RESULTS
A total of 146 patients were included. The incidence of dyslipidemia is 67.1% and DM type 2 is 2.7%. Majority of the participants are male with average age of 30 years old and normal BMI. 28% are smokers and 30% are alcoholic beverage drinkers with normal kidney and liver function test screening. 12 months after HAART, a significant increase was noted in triglyceride levels by 0.78 mg/dl, LDL levels by 0.46 mg/dl and FBS levels by 0.18 mg/dl. The odds ratio of the different first line combination HAART to dyslipidemia and DM type 2 is highest with Lamivudine+ Tenofovir+Nevirapine.

CONCLUSION
Diabetes Mellitus type 2 and dyslipidemia have an increasing incidence in people living with HIV on 1st line HAART. Therefore, regular monitoring and proper management of these diseases is recommended.